Selectivity of NSAIDs for COX-2 and cardiovascular outcome

S R J Maxwell; R A Payne; G D Murray; D J Webb

doi:10.1111/j.1365-2125.2006.02620.x

Selectivity of NSAIDs for COX-2 and cardiovascular outcome

S R J Maxwell, R A Payne, G D Murray, D J Webb

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

8 Citations (Scopus)

Abstract

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) with increased selectivity for the cyclooxygenase-2 (COX-2) isoform reduce gastrotoxicity but may increase adverse cardiovascular events.

METHODS: We searched the literature for studies that reported the odds ratio (OR) for such events following exposure to NSAIDs.

RESULTS: For studies comparing NSAID use with no use, increased COX-2 selectivity was significantly related to cardiovascular risk (log OR) amongst observational studies (R = -0.34, P < 0.001) and randomized controlled trials (RCTs) (R = -0.56, P < 0.001). For studies comparing NSAIDs, difference in selectivity was related to risk for observational studies (R = -0.28, P = 0.005) but not for RCTs (R = -0.23, P = 0.15).

CONCLUSIONS: Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.

Original language	English
Pages (from-to)	243-5
Number of pages	3
Journal	British Journal of Clinical Pharmacology
Volume	62
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2125.2006.02620.x
Publication status	Published - Aug 2006

Keywords

Anti-Inflammatory Agents, Non-Steroidal/adverse effects
Cardiovascular Diseases/chemically induced
Cyclooxygenase 2/metabolism
Humans
Research Design
Risk Factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2125.2006.02620.x

Handle.net

Persistent link

Cite this

@article{f08d18a05eaf4473938ac8b65b84bc2f,

title = "Selectivity of NSAIDs for COX-2 and cardiovascular outcome",

abstract = "BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) with increased selectivity for the cyclooxygenase-2 (COX-2) isoform reduce gastrotoxicity but may increase adverse cardiovascular events.METHODS: We searched the literature for studies that reported the odds ratio (OR) for such events following exposure to NSAIDs.RESULTS: For studies comparing NSAID use with no use, increased COX-2 selectivity was significantly related to cardiovascular risk (log OR) amongst observational studies (R = -0.34, P < 0.001) and randomized controlled trials (RCTs) (R = -0.56, P < 0.001). For studies comparing NSAIDs, difference in selectivity was related to risk for observational studies (R = -0.28, P = 0.005) but not for RCTs (R = -0.23, P = 0.15).CONCLUSIONS: Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.",

keywords = "Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Cardiovascular Diseases/chemically induced, Cyclooxygenase 2/metabolism, Humans, Research Design, Risk Factors",

author = "Maxwell, {S R J} and Payne, {R A} and Murray, {G D} and Webb, {D J}",

year = "2006",

month = aug,

doi = "10.1111/j.1365-2125.2006.02620.x",

language = "English",

volume = "62",

pages = "243--5",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Selectivity of NSAIDs for COX-2 and cardiovascular outcome

AU - Maxwell, S R J

AU - Payne, R A

AU - Murray, G D

AU - Webb, D J

PY - 2006/8

Y1 - 2006/8

N2 - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) with increased selectivity for the cyclooxygenase-2 (COX-2) isoform reduce gastrotoxicity but may increase adverse cardiovascular events.METHODS: We searched the literature for studies that reported the odds ratio (OR) for such events following exposure to NSAIDs.RESULTS: For studies comparing NSAID use with no use, increased COX-2 selectivity was significantly related to cardiovascular risk (log OR) amongst observational studies (R = -0.34, P < 0.001) and randomized controlled trials (RCTs) (R = -0.56, P < 0.001). For studies comparing NSAIDs, difference in selectivity was related to risk for observational studies (R = -0.28, P = 0.005) but not for RCTs (R = -0.23, P = 0.15).CONCLUSIONS: Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.

AB - BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) with increased selectivity for the cyclooxygenase-2 (COX-2) isoform reduce gastrotoxicity but may increase adverse cardiovascular events.METHODS: We searched the literature for studies that reported the odds ratio (OR) for such events following exposure to NSAIDs.RESULTS: For studies comparing NSAID use with no use, increased COX-2 selectivity was significantly related to cardiovascular risk (log OR) amongst observational studies (R = -0.34, P < 0.001) and randomized controlled trials (RCTs) (R = -0.56, P < 0.001). For studies comparing NSAIDs, difference in selectivity was related to risk for observational studies (R = -0.28, P = 0.005) but not for RCTs (R = -0.23, P = 0.15).CONCLUSIONS: Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.

KW - Anti-Inflammatory Agents, Non-Steroidal/adverse effects

KW - Cardiovascular Diseases/chemically induced

KW - Cyclooxygenase 2/metabolism

KW - Humans

KW - Research Design

KW - Risk Factors

U2 - 10.1111/j.1365-2125.2006.02620.x

DO - 10.1111/j.1365-2125.2006.02620.x

M3 - Review article (Academic Journal)

C2 - 16842401

SN - 0306-5251

VL - 62

SP - 243

EP - 245

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 2

ER -

Selectivity of NSAIDs for COX-2 and cardiovascular outcome

Abstract

Keywords

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this